Salvia miltiorrhiza injection ameliorates myocardial ischemia-reperfusion injury via downregulation of PECAM-1

Purpose: To investigate the effect of Salvia miltiorrhiza injection on myocardial ischemia-reperfusion injury and PECAM-1 related pathways. Method: Male Wistar rats were used for establishment of myocardial ischemia-reperfusion model. The rats were randomly assigned to four groups: experimental group, low dose group (Salvia miltiorrhiza injection, 10 mL/kg/day), moderate dose group (Salvia miltiorrhiza injection, 20 mL/kg/day) and high dose group (Salvia miltiorrhiza injection, 40 mL/kg/day). Myocardial ischemia-reperfusion model was established in the four groups. Evans-TTC staining was used to assess relative area of ischemiareperfusion injury. Blood samples were collected for assay of PECAM-1 expression using enzymelinked immunosorbent assay (ELISA). Fresh blood platelets were collected in all groups, and divided into two groups - control group (normal culture) and experimental group (Salvia miltiorrhiza injection). The expression of PECAM-1 in blood platelets was assayed using Western blot. Result: Compared with the experimental group, Salvia miltiorrhiza injection ameliorated myocardial ischemia-reperfusion injury, and decreased the infarction area seen in Evans/TTC staining. PECAM-1 expression in blood was decreased by Salvia miltiorrhiza injection. Blood platelets dysfunction was induced after myocardial ischemia-reperfusion, and the level of PECAM-1 increased. However, Salvia miltiorrhiza injection treatment downregulated the expression of PECAM-1 after myocardial ischemiareperfusion. Conclusion: Salvia miltiorrhiza injection maintains normal function of blood platelets and ameliorates myocardial ischemia-reperfusion injury by decreasing expression of PECAM-1.

Download Full-text

Effect of Iloprost, a Prostacyclin Analogue, on Myocardial Ischemia- Reperfusion Injury

The Heart Surgery Forum ◽

10.1532/hsf.2076 ◽

2019 ◽

Vol 22 (1) ◽

pp. E027-E031 ◽

Cited By ~ 1

Author(s):

Naim Boran Tumer ◽

Gokhan Erol ◽

Atike Tekeli Kunt ◽

Suat Doganci

Keyword(s):

Myocardial Ischemia ◽

Reperfusion Injury ◽

Heart Surgery ◽

Ischemia Reperfusion Injury ◽

Ischemia Reperfusion ◽

Open Heart Surgery ◽

Prostacyclin Analogue ◽

Myocardial Ischemia Reperfusion Injury ◽

Myocardial Ischemia Reperfusion ◽

Experimental Group

Myocardial ischemia-reperfusion injury continues to be observed during open heart surgery. Various experimental models have been developed to overcome this injury and to increase postoperative prognosis. This study was conducted to assess the effect that iloprost, a prostacyclin analogue, can have on myocardial ischemia-reperfusion injury. We evaluated tissue damage by measuring the levels of malonyldialdehyde (MDA), glutathione, and nitric oxide (NO) in tissue and perfusates. In this study, 20 guinea pig hearts were prepared by using the modified Langendorff perfusion apparatus to form control (n = 10) and experimental study groups (n = 10). Following a preischemic period of perfusion and an ischemic period of 20 minutes, control hearts were perfused with Krebs–Henseleit solution. In the experimental group, iloprost (0.45 µg/kg per hour) was included in the perfusates for the last 10 minutes of the preischemic phase. Following cardiac stabilization, heart rate (pulse/min), contractility (mm), and aortic pressure (mmHg) values were recorded at the end of preischemia, postischemia, and reperfusion. Perfusate and tissue analyses for glutathione, MDA, and NO levels were made in each group at the end of experiments. Iloprost was found to have protective effects against myocardial ischemia by means of increased myocardial contractility, decreased tissue/perfusate glutathione levels and inhibited rise of tissue/perfusate MDA observed in the iloprost-treated experimental group. Future investigations on myocardial ischemia-reperfusion injury must evaluate iloprost-related mechanisms.

Download Full-text